Raymond James Financial Services Advisors Inc. Increases Stake in Sanofi (SNY)

Raymond James Financial Services Advisors Inc. grew its position in Sanofi (NYSE:SNY) by 15.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 71,843 shares of the company’s stock after acquiring an additional 9,513 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Sanofi were worth $3,442,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in SNY. Harbour Capital Advisors LLC bought a new position in Sanofi during the 1st quarter worth $113,000. Parallel Advisors LLC raised its position in Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC raised its position in Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its position in Sanofi by 95.8% during the 1st quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock worth $210,000 after purchasing an additional 2,087 shares during the last quarter. Institutional investors own 9.33% of the company’s stock.

Several research analysts recently issued reports on the company. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and set a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $53.50.

TRADEMARK VIOLATION WARNING: “Raymond James Financial Services Advisors Inc. Increases Stake in Sanofi (SNY)” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://ledgergazette.com/2017/10/16/raymond-james-financial-services-advisors-inc-increases-stake-in-sanofi-sny.html.

Sanofi (NYSE SNY) opened at 49.49 on Monday. The company has a market capitalization of $124.29 billion, a price-to-earnings ratio of 11.49 and a beta of 0.87. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.65. The stock has a 50 day moving average price of $49.42 and a 200 day moving average price of $48.19.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the consensus estimate of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.32 earnings per share for the current year.

In other news, major shareholder Sanofi acquired 105,820 shares of the stock in a transaction dated Thursday, August 24th. The stock was purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.00% of the company’s stock.

Sanofi Profile

Sanofi is a healthcare company, focused on

Several other institutional investors and hedge funds have also recently made changes to their positions in SNY. Harbour Capital Advisors LLC bought a new position in Sanofi during the 1st quarter worth $113,000. Parallel Advisors LLC raised its position in Sanofi by 42.5% during the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC raised its position in Sanofi by 33.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in Sanofi by 142.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its position in Sanofi by 95.8% during the 1st quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock worth $210,000 after purchasing an additional 2,087 shares during the last quarter. Institutional investors own 9.33% of the company’s stock.

Several research analysts recently issued reports on the company. Zacks Investment Research lowered Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and set a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $53.50.

TRADEMARK VIOLATION WARNING: “Raymond James Financial Services Advisors Inc. Increases Stake in Sanofi (SNY)” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://ledgergazette.com/2017/10/16/raymond-james-financial-services-advisors-inc-increases-stake-in-sanofi-sny.html.

Sanofi (NYSE SNY) opened at 49.49 on Monday. The company has a market capitalization of $124.29 billion, a price-to-earnings ratio of 11.49 and a beta of 0.87. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.65. The stock has a 50 day moving average price of $49.42 and a 200 day moving average price of $48.19.

Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the consensus estimate of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.32 earnings per share for the current year.

In other news, major shareholder Sanofi acquired 105,820 shares of the stock in a transaction dated Thursday, August 24th. The stock was purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.00% of the company’s stock.

Sanofi Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply